Daiichi Jitsugyo Co (8059) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
9 Sep, 2025Executive summary
Achieved record-high net sales of ¥101,288 million for Q2 FY2024, up 28.8% year-over-year, with significant contributions from the Americas in the Energy Solutions Business.
Operating income nearly doubled, rising 98.0% year-over-year to ¥6,126 million.
Profit attributable to owners increased 74.1% year-over-year to ¥4,290 million, and EPS rose by ¥57.47 to ¥135.23.
Comprehensive income declined 7.2% year-over-year to ¥4,757 million.
Financial highlights
Orders received decreased 5.1% year-over-year, but net sales and all profit metrics saw substantial growth.
Gross profit increased to ¥17,881 million from ¥13,788 million year-over-year, and non-operating income also rose.
Ordinary income rose 104.9% year-over-year to ¥6,214 million.
SG&A and labor costs increased due to hiring more engineers.
Overseas net sales surged, especially in the Americas (+169.6%), driven by lithium-ion battery equipment sales.
Outlook and guidance
FY2024 forecasts: net sales of ¥200,000 million, operating income of ¥10,000 million, and profit attributable to owners of ¥7,300 million.
Q2 progress rates: net sales at 50.6%, operating income at 61.3%, and profit at 58.8% of full-year targets.
Basic earnings per share forecasted at ¥230.11 for the fiscal year ending March 31, 2025.
Dividend payout ratio targeted at 30% of profit, with a forecasted annual dividend of ¥77.0 per share.
Latest events from Daiichi Jitsugyo Co
- Record Q3 profits and strong segment growth support an upwardly revised full-year outlook.8059
Q3 20264 Feb 2026 - Record Q2 sales and profits led to upward revisions in full-year forecasts and dividends.8059
Q2 20267 Nov 2025 - Record Q3 sales and profits, stock split, and strong growth across all segments.8059
Q3 20259 Sep 2025 - Record sales and profits, strong overseas growth, and a conservative outlook for next year.8059
Q4 20259 Sep 2025 - Record Q1 sales and profits driven by Healthcare and Automobile, but outlook is slightly cautious.8059
Q1 20269 Sep 2025 - Strong sales and profit growth, with robust outlook and improved equity ratio.8059
Q1 20259 Sep 2025